A method for sequential protein A-gold immunolabeling is described whereby the binding of second gold probe to the first antibody-protein A-gold complex is reduced to acceptably minimal levels. Immunolabeling of thin sections of embedded pituitary tissue was used as a model system. After an initial immunolabeling for prolactin, sections were incubated in normal serum (rabbit) followed by a monovalent fragment of protein A. These latter two incubations reduced artifactual second gold probe label over prolactinlabeled secretory granules to minimal levels (<<I particle per granule) when sections were subsequently immunolabeled with normal serum. The combination of normal serum and protein A fragment incubations saturates IgG and
Introduction
Since the introduction of protein A-gold probes as immunocytochemical markers at the electron microscopic level (14) they have been widely used, principally because of the broad range of their affinity for antibodies raised in a number of different animal species (12) . Where protein A-gold probes have been used in sequential double labeling studies, however, the presence of artifactual co-localization of the two probe sizes used has been the subject of some debate (3, 19) .
Originally, the method was proposed to be effective because if antibodies from the second immunolabeling step were bound by any free protein A on the first gold probe these antibodies were then believed to be unable to bind the second gold probe ( 5 ) . This beliefwas based on the hypothesis that an IgG molecule could bind only one protein A molecule (13) . Since that study, others (3, 15, 19) have suggested that spurious co-localization of the two gold probes may occur because an IgG molecule can bind more than one protein A molecule (11) .
The problem of artifactual co-localization can be overcome either by use of the selected surface method of Bendayan (2), whereby opposite section faces are immunolabeled for each of the two antibodies under study, or by the use of a very small (3-nm) first protein A-gold probe so that steric hindrance does not allow further binding of antibody or gold probe (15) . Although these two methods protein A binding sites on the fmt antiMy-gold probe complex. The latter is thereafter unable to bind further IgG (and thus gold probe) because of the monovalent nature of the protein A fragment. It is suggested that this methodology may be extended to multiple immunolabeling procedures for electron microscopy. In addition, when used before single labeling this method may be an effective way to minimize nonspecific IgG binding in cases where the tissue or antibody under study may be a problem. ( have been used with success, the latter has the disadvantage that high magnifications are required to determine positivity for the first antibody labeling, and the former requires careful grid manipulation and additional method controls to avoid and assess possible contamination of the opposite section face to that being immunolabeled. Although the selected surface method may be successful for hydrophobic resin-embedded tissue, if one of the more hydrophilic resins has been used the use of this method may then become impossible. Indeed, the present author, while attempting to co-localize prolactin and growth hormone in sheep pituitary tissue and cells embedded in the aromatic acrylic resin LR Gold, found immunoreagent seepage to be a major problem; although Face B to Face A contamination could be avoided (by carbon-coating Face A) (I), Face A to Face B diffusion remained. Eventually, antibodies raised in different donor animals and the relevant second antibody-gold probes were used to achieve successful identification of cells containing both of these hormones (16) .
LR Gold resin has been used with some success in this laboratory to localize a variety of cell components whose antigenicity was not retained, or was at least impaired, by the more common (epoxy) resins (9JO. [16] [17] [18] , and as the research here often demands double immunolabeling studies, commonly with two rabbit antisera, some thought was given to ways of avoiding spurious probe co-localization with the sequential protein A-gold method.
Recently, a fragment of protein A has become commercially available which is monovalent with regard to its binding to IgG molecules (6) . It was hypothesized that if sections immunolabeled with primary antibody and protein A-gold were then exposed to normal serum and subsequently to the protein A fragment, this might then serve to saturate IgG and then protein A binding sites on the first antibody-protein A-gold complex. The present study reports on the testing of the above hypothesis using a model system of (sheep) pituitary tissue immunolabeled initially for prolactin to identify mammotroph cells and then with a second immunolabeling in various concentrations of normal (rabbit) serum.
Materials and Methods

Preparation of Tissue
Sheep pituitary tissue was prepared for immunocytochemistry by a minimal cold fixation procedure (4% formaldehydel0.5 % glutaraldehyde for 3 hr at 4"C), followed by embedding in LR Gold resin (Bio-Rad Microscience Division; Hemel Hempstead, UK) as described previously (16) .
Antibodies
The rabbit anti-prolactin and anti-growth hormone (GH) sera were kindly provided by Professor M. Wallis (University of Sussex); details of these antisera have been described in previous work from this laboratory (16) . The normal rabbit serum was a kind donation from J. Mhlanga (University of Sussex).
Monovalent Protein A and Protein A-Gold Conjugates
The protein A fragment (recombinant; MW 13,885; source, E. cofz) was obtained from Janssen Biochimica (distributors: Cambio Ltd, Cambridge, UK). Protein A-gold probes were obtained from BioCell Research Laboratories (Cardiff, UK) and were used at 1:10 dilution in a modified phosphatebuffered saline (pH 8.2) containing 1% bovine serum albumin, 1 mmol Na-EDTAlliter, 0.05% Tween-20, and 0.02% (w/v) NaN3 (PBSc).
Protein A-Gold Im munolabeling
Thin sections of pituitary tissue were cut with a diamond knife, picked up on formvar-coated 300-mesh nickel grids, and allowed to dry down thoroughly at room temperature.
The precise technical procedures used for immunolabeling in this laboratory have been described in detail previously (16) . In addition to the dilution of the protein A-gold probes, PBS+ was also used as diluent for the antisera and protein A fragment.
follows:
Optimization of the Method. Sections were incubated stepwise as 1. PBS+ blocking step (30 min at room temperature). 2. Rabbit anti-prolactin serum (1:5000, overnight at 4'C). 3. PBS+ rinse (three times for 2 min). 4. Protein A-gold (20-nm, 1 hr at room temperature). 5. PBS+ rinse (three times for 10 min). 6. Normal rabbit serum (undiluted or 1:100 for 2 hr at room temper-7. PBS+ rinse (three times for 2 min). ature). 8 . Protein A fragment (0.2 mglml for 10 min; 0.5 mg/ml for 30 min; 1 mg/ml for 1 hr or 2 mglml for 2 hr at room temperature). 9. PBS+ rinse (five times for 2 min). 10. Normal rabbit serum (l:lO, 1:100, or 1:lOOO for 2 hr at room tem-11. PBS+ rinse (three times for 2 min). 12. Protein A-gold (lo-nm, 1 hr at room temperature). 13 . PBS+ rinse (three times for 10 min). 14. Double glass-distilled water (four times for 3 min). 15 . Stained in saturated aqueous uranyl acetate ( 5 min).
Controls. To assess the effectiveness of the modified treatment (normal serum/monovalent fragment of protein A between the first and second immunolabelings) concurrent control sections were immunolabeled as above, except in Steps 6 to 9 where incubations were in PBS+ alone. perature).
Double Protein A-Gold Immunolabeling
Pituitary sections were double immunolabeled by the procedure outlined in "Optimization of the Method" except for the following: at Step 6 only undiluted normal serum was used; at Step 8 the protein A fragment was used only at a concentration of 1 mg/ml (for 1 hr); and at Step 10 a 1:100 dilution of rabbit anti-GH serum was used.
Checking for Possible Steric Hindrance
Pituitary sections were immunolabeled for prolactin with protein A-gold (20 nm) and incubated with undiluted normal serum and 1 mglml protein A fragment as described above. The sections were then subsequently immunolabeled once more for prolactin (1:lOO) with the smaller (10-nm) protein A-gold probe.
Quantification of Immunolabeling Densities
hmunolabeled sections were examined on a Jeol lOOC electron microscope at 80 kV and micrographs of mammouophs [prolactin (20-nm gold probe)labeled] taken at a magnification of x 40,000. A total of 100 secretory granules from different sections of each immunolabeling experiment were measured from prints of x 80,000 and their areas determined. The numbers of 20-nm and 10-nm gold particles over each secretory granule were then counted so that immunolabeling densities could be determined.
Results
Optimization of the Method
The prolactin labeling of the mammotroph cells of the pituitary tissue sections using a polyclonal rabbit antiserum and protein A-gold probe of 20 nm provided good clean results in the initial immunolabeling step; label was intense [a mean of 22.31 5 0.19 SEM gold particles per secretory granule profile (n = lOoO)] and confined to granule profiles. With the specific incubation and rinse durations and the buffer employed in this work the nonspecific background was very low, as has been previously shown and quantified (label per pm2 nucleus) with this tissue and antiserum where a second antibody (goat anti-rabbit)-gold probe was used (16) .
When prolactin-immunolabeled sections were subsequently immunolabeled with normal serum, an artifactual co-localization of the second gold probe with the first resulted. This second probe localization is artifactual because it represents binding to the first antibody-protein A-gold complex (and not to a specific tissue epitope). Normal serum antibodies bound to free protein A molecules on the first gold probe and were subsequently labeled by the second probe; in addition, the second gold probe bound to any prolactin antibodies unlabeled by the first gold probe.
The amount of this spurious second gold probe labeling with three dilutions of normal serum is quantified in Cble 1 (untreated). With a 1:10 normal serum incubation, the second protein A-gold particle density was very high (a mean of 16.29 gold particles per secretory granule profile; Figure la) , while even at a dilution of 1:1000 the density was significant (a mean of 2.82 partides per secretory granule profile).
The remainder of Table 1 summarizes the effects of various concentrations and durations of normal serum and protein A fragment incubations [applied to sections between the first (prolactin) and second (normal serum) immunolabelings] on this artifactual label. The optimal reduction in the latter was achieved with undiluted normal serum (2 hr) followed by 1 mglml protein A fragment (60 min); this treatment reduced artifactual label to 842% of that of untreated sections, so that there were >>1 second gold particles per secretory granule after immunolabeling with 1:lOO or 1:IOOO normal serum. Even with undiluted normal serum and only 0.5 mg/ml protein A fragment (30 min), followed by immunolabeling with 1:100 normal serum, visual appraisal of the sections showed the results to be "clean" (Figure Id) . Increasing the concentration and duration of the protein A fragment to 2 mglml for 2 hr did not improve reduction in artifactual label. Rather, there was a slight increase in the amount of second gold probe. This may well reflect a situation of excess protein A fragment, resulting in its dissociation from the first antibody-first gold probe-normal serum complex, and thereby allowing binding of the second gold probe to the latter.
Double Protein A-Gold Inzmunol'abeling
Pituitary sections were double labeled for prolactin and GH with the described monovalent protein A method using the conditions found to be optimal (2 hr undiluted normal serum; 1 hr, 1 mglml protein A fragment). The sections exhibited "clean" labeling for each hormone, with gold particles confined to the secretory granules. There was a minimal amount of co-localization of the two different-sized gold probes used (Figure 2a ).
Ckieching for possible Steric Hindrance
Pituitary sections immunolabeled for prolactin (at a dilution of 1:IOOO) and then once more for prolactin (at a dilution of 1:loo) with the optimal monovalent protein A method described above showed a high density of second gold particles over secretory granules labeled with the first gold probe (Figure 2b ). This second gold probe label density was well in excess of that observed with a similar dilution of normal serum (compare with Figure Id ).
Discussion
For successful sequential protein A-gold immunolabeling an es- Table 1 
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. , sential prerequisite is that the first antibody-protein A-gold complex is subsequently unable to bind the second gold probe used to label the second antiserum incubation; the latter will occur if there are any protein A binding sites on this complex. The addition of excess protein A after the first immunolabeling procedure (I) may serve to saturate these sites present on the first antibody. However, there will still be sites available on any second-incubation IgG molecules bound to protein A molecules coating first gold particles not involved in binding to the first antibody; these sites will be present if IgG molecules are capable of binding more than one protein A molecule, as has been shown (ll), and the effects on spurious localization of gold probes that may result have been discussed (15, 16, 19) . Such instances of second IgG binding to the first probe are likely, as a 15-nm protein A-gold probe, for example, has been estimated to have some 40 or 60 molecules of protein A adsorbed on each gold particle (5,7) .
The present study describes a methodology to minimize artifac-' C tual probe co-localization which can be used as an alternative to the selected surface method ( 2 ) when embedment in more hydrophilic resin creates problems of immunoreagent seepage. Successful sequential protein A-gold labeling, with a relatively large first gold particle size, can be performed upon the same section face with minimal artifact. The proposed mechanism of action of the technique is shown diagrammatically in Figure 3 .
After the first immunolabeling step, successive incubations with normal rabbit serum and protein A fragment render the first antibody-first protein A-gold complex unable to bind further IgG molecules or protein A-gold during a second immunolabeling; this is brought about by the saturation of IgG binding sites (on any unbound protein A on the first gold probe) by the normal serum, and the saturation of [F(c)] protein A binding sites on these normal serum IgG molecules (and on any first antiserum IgG molecules not bound with the first gold probe) by the protein A frag ment. The monovalent nature of this protein A fragment ensures no further binding of IgG molecules and thus no additional protein A-gold labeling. Even with a second incubation with normal serum at a concentration (1:lo) much higher than that which would normally be used for an antiserum of reasonable titer, the level of artifactual second gold probe labeling is low. The ability to use a relatively large probe size first may be beneficial because the second immunolabeling step often produces label densities that are lower than that for single labeling with the same antiserum (Thorpe JR, unpublished observations), and the use of a smaller probe for the second immunolabeling will increase the label density.
The double-labeling methodology described herein results in the formation of a large complex before the second immunolabeling. This complex consists of first antibody, first protein A-gold particle(s), normal serum antibodies, and monovalent protein A molecules. There is the possibility that this bulky complex might hinder the subsequent labeling of a nearby epitope. Cells containing both prolactin and GH immunolabel were not found in the pituitary sections double labeled during the course of this work. This may well be simply because these cells (somatomammotrophs) are extremely rare in sheep pituitary tissue (16), rather than being a proof that steric hindrance is interfering with nearby epitope labeling. To check for possible steric hindrance, therefore, sections were immunolabeled for prolactin, incubated with normal serum and protein A fragment, and then immunolabeled once more for prolactin. Considerable numbers of second gold particles were observed over prolactin-containing secretory granules labeled with first gold particles (Figure 2b ). This shows that the described methodology should be suitable in studies where the specific epitopes under investigation may be closely associated.
To summarize, the monovalent protein A method described herein may be the method of choice where studies involve embedding in hydrophilic resins and the antisera available have an affinity for protein A. It should be noted, however, that if the IgG molecules from the donor species possess protein A binding sites in their F(ab) portions, the described methodology will be flawed; in this case, IgG molecules from the initial immunolabeling will still have sites available for second gold probe binding as the protein A fragment binds only F(c) receptors. Antiserum raised in rabbit (as used herein) have an IgG population with low-avidity (4.20) or no (8) F(ab) protein A binding sites; perhaps the minor amount of residual second probe shown here after F(c) binding site saturation may reflect a low level of F(ab) binding.
There is the possibility that the described methodology might be extended to multiple labeling, perhaps with 20-, lo-, 5-, and then 3-nm gold probes, with each immunolabeling step being subsequently "masked" by treatment with normal serum and protein A fragment before further labeling. In addition, the method could be applicable to the localization of four antigens within the same section by double protein A-gold labeling each face of a section taken from a sample embedded in hydrophobic resin (where possible immunoreagent contamination is absent). Finally, the method should be useful as a pre-treatment in single-label studies to reduce nonspecific IgG binding in cases where an antiserum may be of low titer (and therefore used at high concentration) or where the tissue to be labeled has intrinsically high nonspecific binding.
